Truist Securities Maintains Buy on CVS Health, Lowers Price Target to $103
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst David Macdonald maintains a Buy rating on CVS Health (NYSE:CVS) but lowers the price target from $109 to $103.
June 20, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on CVS Health, but lowers the price target from $109 to $103.
The news of Truist Securities maintaining a Buy rating on CVS Health is positive for the stock. However, the lowering of the price target from $109 to $103 may create some uncertainty among investors. The overall impact on the stock price in the short term is expected to be neutral, as the Buy rating is still maintained.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100